Point-of-care diagnosis of esophageal cancer in lmics
Active Cooperative Agreement Awarded Last action
- Award ID
- U01CA279866
- Recipient
-
The Johns Hopkins University UEI FTMTDMBR29C7
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $4,087,657
Award facts
- Assistance listing
- 93.394 Cancer Detection and Diagnosis Research
- Completion date 66% complete
- Place of performance
- Baltimore, MD 21205, USA
Award details come from USAspending.gov.
Description
- Abstract
- Despite substantial progress in clinical approaches to squamous cancer of the esophagus (escc), which causes most esophageal cancers (EC) in the world, this deadly tumor usually occurs at late disease stages, with very poor survival. Restricted availability of endoscopy (EGD), along with rarity and delays in histology, impairs detection of escc in lmics, adversely impacting our ability to treat this disease effectively. Thus, in lmics, inexpensive, safe, locally performable strategies for detecting escc are necessary to identify high-risk patients and refer them quickly to suitable diagnostic and therapeutic options. Therefore, a diagnostic approach featuring a retrievable swallowed sponge-on-a-string to gather esophageal specimens for molecular testing, combined with a point-of-care (POC) magnetofluidic chip for sample processing and DNA methylation detection, is proposed. The string-sponge is less expensive, more noninvasive, more convenient, and more rapid than EGD with biopsy. The magnetofluidic chip streamlines DNA purification, DNA bisulphite treatment, and PCR detection of methylation markers into a single POC apparatus. This approach does not necessitate EGD, can be performed in remote areas with portable energy supplies and does not require extensive medical training, and is thereby amenable to implementation in lmics. Our specific aims are: 1: using a sponge-capsule swallowed/tethered collection device, to construct a methylation marker-based strategy to detect escc. In 100 escc and 100 benign control patients, we propose (1) building a multivariate model containing biomarker candidates; (2) carrying out feedback-feasibility meetings with health care and endoscopy personnel at makerere university hospitals to fine-tune eventual POC usage; 2: in order to achieve a sample-to-answer assay, to implement DNA extraction, bisulfite treatment, and methylation-specific PCR into a magnetofluidic chip with dried reagents. We'LL use magnetofluidic techniques to streamline cell lysis, DNA extraction, bisulphite treatment, and methylation-specific PCR into a compact chip built from cheap thermoplastic materials. In addition, we'LL lyophilize reagents and use heat- deployed wax sealant plugs to permit storage at room temperature. In this fashion, we will fashion a sample-to- answer assay that is easy to use, inexpensive, and free of cold-chain steps; 3: in order to achieve fully automatic high-speed biomarker assaying, to design a small, light apparatus. We'LL engineer an instrument containing programmable magnetic actuation, temperature control, and detection of fluorescence to execute the test in a chip with very little user input. We'LL also design the apparatus to be small, light, easy to operate, portable electricity-powered, and mobile phone-controlled to ease integration with lmic-based clinical tasking; and 4: using our POC approach to carry out a diagnostic pilot study of escc in uganda. While applying the magnetofluidic chip and apparatus used in aim 2 and aim 3, we'LL carry out a trial to measure specificity and sensitivity in 120 EGD-confirmed cases of escc and 360 benign disease control patients in kampala, uganda.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $62,247 | |
| Amendment | $512,303 | |
| Amendment | $512,303 | |
| Amendment | $0 | |
| Amendment | $62,251 | |
| Amendment | $544,343 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $576,573 | |
| Amendment | $576,573 | |
| Amendment | $620,532 | |
| Original award | $620,532 |
Show all 14
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| Mbarara University Of Science And Technology | $124,498 | |
| Mbarara University Of Science And Technology | $98,594 |
Quick answers
Who received award U01CA279866?
U01CA279866 was awarded to The Johns Hopkins University by National Cancer Institute (National Institutes of Health) on July 1, 2023.
How much is award U01CA279866 worth?
$4,087,657 has been obligated on U01CA279866.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award